Details of the Drug

General Information of Drug (ID: DMCJXUD)

Drug Name

CSL200

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell anaemia	3A51	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Gene therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04091737) A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human gamma-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease. U.S.National Institutes of Health.